Medical XpressVigil immunotherapy tolerated well for recurrent ovarian CA TxMedical Xpress(HealthDay)—Vigil immunotherapy shows good tolerability for recurrent ovarian cancer patients, and PARP 7, a poly(ADP-ribose) polymerase protein, may play a signi… Continue reading
Genetic Literacy ProjectCRISPR/Cas9 Adapted as "Mutation Prevention System"Genetic Engineering & Biotechnology NewsScientists have developed methods for classifying these point mutations, but it is much harder to target these cells specifical… Continue reading
|
AveXis gene therapy awarded SAKIGAKE designation for SMA Type 1
Seeking Alpha Japan’s Ministry of Health, Labour and Welfare has granted SAKIGAKE Designation for AveXis’ (NASDAQ:AVXS) AVXS-101, for the treatment of spinal muscular atrophy (SMA) Type 1. The designation was based on data from the Phase 1 clinical trial of the … |
The Scientist |
Texas Stem Cell Law Opens Door for Controversial Treatments
The Scientist Direct-to-consumer stem cell clinics, influential Texas politicians—some with ties to Celltex—and some patients eager for alternative therapeutic options applaud the law. But scientists question the cells’ efficacy, and bioethicists voice concerns … Stem Cell Therapy for Crohn’s Disease Approved in EuropeLabiotech.eu (blog) New Jersey is about to legalize marijuana. Our own stem cells …PhillyVoice.com Takeda’s off-the-shelf stem cell therapy approved in EuropeBioPharma-Reporter.com Medical Xpress –PMLiVE –Daily Mail all 29 news articles » |
EconoTimes |
Form 8-K AveXis, Inc. For: Mar 27
StreetInsider.com Chicago, Ill. (March 27, 2018) — AveXis, Inc. (NASDAQ: AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases, today announced that Japan’s Ministry of … QS Investors LLC Invests $156000 in AveXis Inc (AVXS)Macon Daily |